

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

CLARIFICATION ANNOUNCEMENT

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”) on a voluntary basis.

On January 26, 2024, the Company became aware of a draft bill (the “**Draft Bill**”) introduced in the United States of America (the “**U.S.**”) House of Representatives, which proposed to restrict U.S. executive agencies from contracting with certain biotechnology providers. This Draft Bill is subject to further review and modification by U.S. legislators.

The Draft Bill contains a misleading description of the background of Dr. Zhisheng Chen (“**Dr. Chen**”), the Chief Executive Officer and Executive Director of the Company. The Draft Bill references an academic designation granted as a courtesy after a one-time guest lecture in 2013, a common practice in Chinese universities. The Company’s understanding is that Dr. Chen had no other engagement with the institution prior to or since then. He has neither worked for the Academy of Military Medical Sciences or any military-affiliated institution, nor has he received compensation from military-affiliated institutions.

The Company’s global business operations remain as usual. The Company is committed to supporting its customers globally and to operating with the highest standards of compliance and in accordance with the applicable laws and regulations of all jurisdictions where it has business operations.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, January 29, 2024

*As at the date of this announcement, the board of directors (“**Directors**”) of the Company comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.*

* *For identification purpose only*